UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported)  December 10, 2003

 

 

 

Item 5.    Other Events.

 

Certain officers of ABIOMED, Inc. have informed ABIOMED that they have recently entered into or amended, or intend to enter into or amend, stock diversification plans in order to sell ABIOMED common stock in accordance with all applicable SEC and NASDAQ rules. The diversification plans will have been or will be adopted under Rule 10b5-1 of the Securities Exchange Act of 1934 and are designed to avoid real or perceived conflicts of interest which could arise from our officers’ involvement with the Company, while enabling our officers to diversify their investment portfolios.  Under the diversification plans our officers have authorized or will authorize an independent third party to sell shares of ABIOMED common stock held directly or beneficially by them. Such sales, if any, will be conducted over a sales period generally not shorter than one year and will be executed in accordance with guidelines established by the officers at the beginning of each sales period.  In addition, each officer entering into a diversification plan has informed us that he or she will publicly disclose any stock sales made under the diversification plan as required by the securities laws.

 

 

2

 

SIGNATURE

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunder duly authorized.

 

 

	ABIOMED, Inc.
Date: December 10, 2003	/s/ Charles B. Haaser
	Charles B. Haaser
	Controller Principal Accounting Officer Principal Financial Officer

 

3